Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
957 USD +2.07% Intraday chart for Regeneron Pharmaceuticals, Inc. +8.36% +8.96%
May. 03 Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept MT
May. 03 Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 41,049 50,990 66,029 77,057 93,403 105,448 - -
Enterprise Value (EV) 1 35,291 50,098 56,196 77,057 84,542 96,955 93,185 87,271
P/E ratio 20.3 x 15.8 x 8.77 x 18.9 x 25.3 x 26.8 x 24.5 x 20.8 x
Yield - - - - - - - -
Capitalization / Revenue 5.22 x 6 x 4.11 x 6.33 x 7.12 x 7.64 x 7.08 x 6.64 x
EV / Revenue 4.49 x 5.9 x 3.5 x 6.33 x 6.45 x 7.03 x 6.26 x 5.5 x
EV / EBITDA 10.3 x 11.8 x 5.71 x 12.7 x 15.2 x 17.1 x 15.4 x 13.1 x
EV / FCF 17.6 x 25 x 8.61 x 17.4 x 21.8 x 19.2 x 19 x 15.8 x
FCF Yield 5.67% 4% 11.6% 5.74% 4.58% 5.21% 5.27% 6.34%
Price to Book 3.7 x 4.71 x 3.56 x 3.41 x 3.64 x 3.44 x 3.03 x 2.59 x
Nbr of stocks (in thousands) 109,323 105,544 104,556 106,802 106,347 110,186 - -
Reference price 2 375.5 483.1 631.5 721.5 878.3 957.0 957.0 957.0
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7,863 8,497 16,072 12,173 13,117 13,798 14,896 15,875
EBITDA 1 3,420 4,244 9,835 6,060 5,547 5,684 6,043 6,642
EBIT 1 2,210 3,577 8,947 5,719 5,126 5,106 5,571 6,140
Operating Margin 28.1% 42.09% 55.67% 46.98% 39.08% 37% 37.4% 38.68%
Earnings before Tax (EBT) 1 2,429 3,810 9,326 4,859 4,199 4,244 4,908 5,438
Net income 1 2,116 3,513 8,075 4,338 3,954 4,026 4,452 5,190
Net margin 26.91% 41.35% 50.25% 35.64% 30.14% 29.18% 29.89% 32.69%
EPS 2 18.46 30.52 71.97 38.22 34.77 35.69 38.99 45.96
Free Cash Flow 1 2,000 2,004 6,529 4,425 3,875 5,054 4,910 5,535
FCF margin 25.44% 23.58% 40.63% 36.35% 29.54% 36.63% 32.97% 34.87%
FCF Conversion (EBITDA) 58.5% 47.2% 66.39% 73.01% 69.86% 88.9% 81.26% 83.34%
FCF Conversion (Net income) 94.55% 57.03% 80.86% 101.99% 98.02% 125.52% 110.3% 106.66%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,952 2,965 2,857 2,936 3,414 3,162 3,158 3,363 3,434 3,145 3,369 3,553 3,712 3,594 3,664
EBITDA 1 2,903 1,558 1,344 1,488 1,637 1,315 1,351 1,488 1,395 - 1,326 1,493 1,653 1,193 1,285
EBIT 1 2,640 1,483 1,285 1,413 1,537 1,215 1,248 1,382 1,282 1,028 1,203 1,346 1,406 1,311 1,369
Operating Margin 53.31% 50.03% 44.99% 48.12% 45.02% 38.43% 39.51% 41.11% 37.33% 32.68% 35.7% 37.88% 37.87% 36.49% 37.37%
Earnings before Tax (EBT) 1 2,503 1,061 963.2 1,510 1,325 858 1,083 1,111 1,148 700.7 1,122 1,205 1,172 1,233 1,339
Net income 1 2,229 973.5 852.1 1,316 1,197 817.8 968.4 1,008 1,160 722 1,013 1,118 1,152 1,109 1,155
Net margin 45.01% 32.83% 29.82% 44.81% 35.06% 25.86% 30.66% 29.97% 33.77% 22.96% 30.05% 31.47% 31.02% 30.86% 31.52%
EPS 2 19.69 8.610 7.470 11.66 10.50 7.170 8.500 8.890 10.19 6.270 8.887 9.794 10.06 9.795 10.19
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/4/22 5/4/22 8/3/22 11/3/22 2/3/23 5/4/23 8/3/23 11/2/23 2/2/24 5/2/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 5,757 891 9,833 - 8,862 8,492 12,263 18,176
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 2,000 2,004 6,529 4,425 3,875 5,054 4,910 5,535
ROE (net income / shareholders' equity) 28.5% 33.2% 54.2% 24.9% 20.7% 18.4% 17.3% 16.7%
ROA (Net income/ Total Assets) 15.9% 22% 37.9% 18.9% 16.2% 14% 11.9% 12.5%
Assets 1 13,270 15,984 21,299 22,956 24,412 28,757 37,455 41,483
Book Value Per Share 2 102.0 102.0 178.0 212.0 241.0 278.0 316.0 369.0
Cash Flow per Share 2 21.20 22.70 63.10 44.20 40.40 49.00 49.90 55.40
Capex 1 430 615 552 590 719 855 766 776
Capex / Sales 5.46% 7.23% 3.43% 4.85% 5.48% 6.2% 5.14% 4.89%
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/2/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
957 USD
Average target price
1,033 USD
Spread / Average Target
+7.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 101B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 103B
ARGENX SE Stock argenx SE
+4.40% 23.07B
BIONTECH SE Stock BioNTech SE
-12.15% 22.23B
GENMAB A/S Stock Genmab A/S
-4.36% 18.05B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.07B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.35B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.53% 8.36B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Financials Regeneron Pharmaceuticals, Inc.